Compare
Twist Bioscience Corp vs Tarsus Pharmaceuticals, Inc. vs ADMA Biologics, Inc. vs Immunocore Holdings plc
| Latest fiscal year | Twist Bioscience Corp TWST | Tarsus Pharmaceuticals, Inc. TARS | ADMA Biologics, Inc. ADMA | Immunocore Holdings plc IMCR |
|---|---|---|---|---|
| Year ended | 2026-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $459.43M | $451.36M | $510.17M | $400.02M |
| Revenue growth (YoY) | +22.0% | +146.7% | +19.6% | +29.0% |
| Gross margin | 52.4% (computed) | n/a | 57.4% | n/a |
| Operating margin | -30.4% | -15.7% | 37.5% | -11.3% |
| Net margin | -28.3% | -14.7% | 28.8% | -8.9% |
| Net income | -$130.20M | -$66.42M | $146.93M | -$35.51M |
| EPS (Diluted) | -$2.08 | -$1.59 | $0.60 | -$0.71 |
| Operating cash flow | -$41.43M | -$12.45M | $50.40M | -$10.71M |
| Free cash flow | -$89.01M | -$22.31M | $27.82M | -$15.05M |
| Cash & equivalents | $533.99M | $183.64M | $87.63M | $467.71M |
| Total assets | $1.12B | $562.16M | $624.24M | $1.07B |
| Total liabilities | $233.79M | $218.73M | $146.92M | $686.24M |
| Shareholders' equity | $888.02M | $343.43M | $477.32M | $381.03M |
| Return on year-end equity | -14.7% | -19.3% | 30.8% | -9.3% |
| Shares outstanding | 67.81M | 42.55M | 237.87M | 50.69M |
Revenue, most recent five fiscal years
| Fiscal year | Twist Bioscience Corp | Tarsus Pharmaceuticals, Inc. | ADMA Biologics, Inc. | Immunocore Holdings plc |
|---|---|---|---|---|
| Latest | $459.43M Ended 2026-09-30 | $451.36M Ended 2025-12-31 | $510.17M Ended 2025-12-31 | $400.02M Ended 2025-12-31 |
| 1 year earlier | $376.57M Ended 2025-09-30 | $182.95M Ended 2024-12-31 | $426.45M Ended 2024-12-31 | $310.20M Ended 2024-12-31 |
| 2 years earlier | $312.97M Ended 2024-09-30 | $17.45M Ended 2023-12-31 | $258.21M Ended 2023-12-31 | $249.43M Ended 2023-12-31 |
| 3 years earlier | $245.11M Ended 2023-09-30 | $25.82M Ended 2022-12-31 | $154.08M Ended 2022-12-31 | $174.36M Ended 2022-12-31 |
| 4 years earlier | $203.56M Ended 2022-09-30 | $57.03M Ended 2021-12-31 | $80.94M Ended 2021-12-31 | $36.48M Ended 2021-12-31 |